Asthma therapy continues to evolve as asthma is further understood as a heterogenous disorder. Many patients with asthma have an allergic component, such that sensitization and exposure to allergens trigger symptoms. Environmental allergen mitigation strategies have shown mixed results in improving clinical outcomes but are likely most effective as multicomponent strategies tailored to a patient’s specific allergic sensitization. With a goal of decreasing asthma symptoms and exacerbations, pharmacotherapy and specifically use of inhaled corticosteroids remain foundational to asthma management. Recent guidelines recommend considering an inhaled corticosteroid plus formoterol, a long-acting beta-agonist with rapid onset of bronchodilation, for use as needed in patients with intermittent asthma instead of short-acting bronchodilator alone. Strategies to titrate medication requirements based on severity and control of the patient’s asthma are commonly used. Allergen immunotherapy represents a treatment option which can drive immunologic changes to improve asthma control while on therapy and even after stopping. It is effective in the treatment of allergic asthma and should be considered in appropriate patients but does have associated risks.